Holen Sie sich die Stockscreener-App
8.41
11.19%
-1.06
Handel nachbörslich:
8.37
-0.04
-0.48%
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Wednesday - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) 12% loss last week hit both individual investors who own 37% as well as institutions - Simply Wall St
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Contineum concludes enrolment in Phase II multiple sclerosis therapy trial - MSN
Enrollment complete in Phase 2 trial of remyelination therapy for RRMS - Multiple Sclerosis News Today
Contineum Therapeutics (NASDAQ:CTNM) Earns “Outperform” Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics' (CTNM) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference - Quantisnow
Contineum Therapeutics, Inc. Completes Enrollment in Phase 2 PIPE-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis - Marketscreener.com
Barclays PLC Raises Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Geode Capital Management LLC Sells 27,745 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
State Street Corp Raises Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest Update - MarketBeat
When the Price of (CTNM) Talks, People Listen - Stock Traders Daily
Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4) - Quantisnow
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
(CTNM) Proactive Strategies - Stock Traders Daily
Charles Schwab Investment Management Inc. Sells 8,477 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Franklin Resources Inc. Acquires 820,542 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
BNP Paribas Financial Markets Acquires 829 Shares of Farmers National Banc Corp. (NASDAQ:FMNB) - Defense World
BNP Paribas Financial Markets Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
BNP Paribas Financial Markets Has $129,000 Stock Holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire
Contineum Therapeutics' SWOT analysis: biotech stock shows promise amid risks - Investing.com
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket - Benzinga
Fmr LLC Raises Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
(CTNM) On The My Stocks Page - Stock Traders Daily
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Shares Sold by Suvretta Capital Management LLC - MarketBeat
Contineum Therapeutics chief scientific officer sells stock worth $16,177 By Investing.com - Investing.com Nigeria
Contineum Therapeutics chief scientific officer sells stock worth $16,177 - Investing.com India
Avidity Biosciences to Participate in Upcoming Investor Conference - Quantisnow
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference - BioSpace
Contineum Therapeutics chief scientific officer sells $101,420 in stock By Investing.com - Investing.com Australia
Contineum Therapeutics chief scientific officer sells $101,420 in stock - Investing.com
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - BioSpace
(CTNM) Trading Signals - Stock Traders Daily
Sectoral Asset Management Inc's Strategic Acquisition in Contine - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Yahoo Finance
Contineum Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Contineum Therapeutics Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
Contineum Therapeutics' SWOT analysis: promising pipeline drives stock outlook - Investing.com India
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):